/주식/ABCL
ABCL

ABCL

USD

AbCellera Biologics Inc. Common Shares

$3.150-0.050 (-1.563%)

실시간 가격

Healthcare
생명공학
캐나다

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$3.200

고가

$3.310

저가

$3.080

거래량

8.00M

기업 기본 정보

시가총액

940.2M

산업

생명공학

국가

Canada

거래 통계

평균 거래량

4.49M

거래소

NMS

통화

USD

52주 범위

저가 $1.891현재가 $3.150고가 $3.68

관련 뉴스

Analyst Upgrades

Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10

Truist Securities analyst Robyn Karnauskas maintains AbCellera Biologics with a Buy and lowers the price target from $28 to $10.

더 보기
Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10
BusinessWire

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial

더 보기
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
BusinessWire

AbCellera Reports Q1 2025 Business Results

AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a

더 보기
AbCellera Reports Q1 2025 Business Results
BusinessWire

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Preclinical data on AbCellera's PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies AbCellera (NASDAQ:ABCL) today announced new

더 보기
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025